Evotec AG today announced that CENTOGENE AG, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-centogene-sign-global-strategic-partnership-on-drug-discovery-projects-in-rare-genetic-diseases-5715